Publications

2017

Central role of myeloid MCPIP1 in protecting against LPS-induced inflammation and lung injury., Y. Li; X. Huang; S. Huang; H. He; T. Lei; F. Saaoud; X.Q. Yu; A. Melnick; A. Kumar; C.J. Papasian; D. Fan; M. Fu, Signal Transduct Target Ther, 2017, 2, , p.17066, (2017) PubMed

Genetic and epigenetic inactivation of controls mTORC1 and response to EZH2 inhibition in follicular lymphoma., E. Oricchio; N. Katanayeva; M.Christine Donaldson; S. Sungalee; J.P. Pasion; W. Béguelin; E. Battistello; V.R. Sanghvi; M. Jiang; Y. Jiang; M. Teater; A. Parmigiani; A.V. Budanov; F.Chun Chan; S.P. Shah; R. Kridel; A.M. Melnick; G. Ciriello; H.G. Wendel, Sci Transl Med, 2017 06 28, 9, 396, p., (2017) PubMed

DNA Methylation-Based Biomarkers., L. Cerchietti; A. Melnick, J Clin Oncol, 2017 03, 35, 7, p.793-795, (2017) PubMed

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas., Y. Jiang; A. Ortega-Molina; H. Geng; H.Y. Ying; K. Hatzi; S. Parsa; D. McNally; L. Wang; A.S. Doane; X. Agirre; M. Teater; C. Meydan; Z. Li; D. Poloway; S. Wang; D. Ennishi; D.W. Scott; K.R. Stengel; J.E. Kranz; E. Holson; S. Sharma; J.W. Young; C.S. Chu; R.G. Roeder; R. Shaknovich; S.W. Hiebert; R.D. Gascoyne; W. Tam; O. Elemento; H.G. Wendel; A.M. Melnick, Cancer Discov, 2017 01, 7, 1, p.38-53, (2017) PubMed

MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia., N.S. Saba; D.H. Wong; G. Tanios; J.R. Iyer; P. Lobelle-Rich; E.L. Dadashian; D. Liu; L. Fontan; E.K. Flemington; C.M. Nichols; C. Underbayev; H. Safah; A. Melnick; A. Wiestner; S.E.M. Herman, Cancer Res, 2017 12 15, 77, 24, p.7038-7048, (2017) PubMed

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells., L.P. Vu; C. Prieto; E.M. Amin; S. Chhangawala; A. Krivtsov; N. Calvo-Vidal; T. Chou; A. Chow; G. Minuesa; S.Mi Park; T.S. Barlowe; J. Taggart; P. Tivnan; R.P. Deering; L.P. Chu; J.A. Kwon; C. Meydan; J. Perales-Paton; A. Arshi; M. Gönen; C. Famulare; M. Patel; E. Paietta; M.S. Tallman; Y. Lu; J. Glass; F.E. Garret-Bakelman; A. Melnick; R. Levine; F. Al-Shahrour; M. Järås; N. Hacohen; A. Hwang; R. Garippa; C.J. Lengner; S.A. Armstrong; L. Cerchietti; G.S. Cowley; D. Root; J. Doench; C. Leslie; B.L. Ebert; M.G. Kharas, Nat Genet, 2017 Jun, 49, 6, p.866-875, (2017) PubMed

Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model., W. Du; R. Goldstein; Y. Jiang; O. Aly; L. Cerchietti; A. Melnick; O. Elemento, Cancer Res, 2017 04 15, 77, 8, p.1818-1830, (2017) PubMed

CD99 is a therapeutic target on disease stem cells in myeloid malignancies., S.S. Chung; W.S. Eng; W. Hu; M. Khalaj; F.E. Garrett-Bakelman; M. Tavakkoli; R.L. Levine; M. Carroll; V.M. Klimek; A.M. Melnick; C.Y. Park, Sci Transl Med, 2017 01 25, 9, 374, p., (2017) PubMed

2016

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling., O.A. Guryanova; K. Shank; B. Spitzer; L. Luciani; R.P. Koche; F.E. Garrett-Bakelman; C. Ganzel; B.H. Durham; A. Mohanty; G. Hoermann; S.A. Rivera; A.G. Chramiec; E. Pronier; L. Bastian; M.D. Keller; D. Tovbin; E. Loizou; A.R. Weinstein; A.Rodriguez Gonzalez; Y.K. Lieu; J.M. Rowe; F. Pastore; A.Sophia McKenney; A.V. Krivtsov; W.R. Sperr; J.R. Cross; C.E. Mason; M.S. Tallman; M.E. Arcila; O. Abdel-Wahab; S.A. Armstrong; S. Kubicek; P.B. Staber; M. Gönen; E.M. Paietta; A.M. Melnick; S.D. Nimer; S. Mukherjee; R.L. Levine, Nat Med, 2016 12, 22, 12, p.1488-1495, (2016) PubMed

Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia., Z. Chen; S. Shojaee; M. Buchner; H. Geng; J.Woong Lee; L. Klemm; B. Titz; T.G. Graeber; E. Park; Y.Xim Tan; A. Satterthwaite; E. Paietta; S.P. Hunger; C.L. Willman; A. Melnick; M.L. Loh; J.U. Jung; J.E. Coligan; S. Bolland; T.W. Mak; A. Limnander; H. Jumaa; M. Reth; A. Weiss; C.A. Lowell; M. Müschen, Nature, 2016 06 02, 534, 7605, p.138, (2016) PubMed